Trials / Withdrawn
WithdrawnNCT04132011
Dosing Intervals of Opioid Medication for Chronic Pain
Examining the Relationship Amongst Opioid Subjective Effects and Pharmacokinetics of Extended Release Opioids at Shortened Dosing Intervals in Patients With Chronic Pain: a Randomized, Blinded, N-of-1 Case Series Feasibility Study
- Status
- Withdrawn
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to determine the feasibility of an n-of-1, randomized, double blind, placebo controlled case series to examine effects of extended release opioids when used at intervals shorter than recommended by the manufacturer by people with chronic pain.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Extended Release Opioid Formulation, Shortened Intervals | Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours |
| DRUG | Extended Release Opioid Formulation, Standard intervals | Extended release opioid, individualized total daily dose, dosing interval is every 12 hours |
| DRUG | Placebo oral tablet | Lactose pill manufactured to mimic extended release opioid formulation |
Timeline
- Start date
- 2019-05-01
- Primary completion
- 2020-03-08
- Completion
- 2020-03-08
- First posted
- 2019-10-18
- Last updated
- 2020-03-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT04132011. Inclusion in this directory is not an endorsement.